E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during this treatment. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Fraction of patients with hematologic improvement according to modified IWG criteria (reduction of transfusions and/or increase in Hb, improvement of neutropenia and thrombocytopenia) |
|
E.2.2 | Secondary objectives of the trial |
- Evaluate the safety and tolerability profile of deferasirox in MDS patients -Effectiveness of iron depletion -Correlation between hematological improvement and effectiveness of iron depletion -Development of bone marrow morphology -Correlation between hematological improvement and pretreatment parameters. Extension of this analysis to MDS patients on deferasirox within the licensed indication (more severe iron overload) -overall survival -AML-free survival
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-MDS of subtype RA, RARS, RCMD, RCMD-RS (i.e. lower risk) -RAEB I allowed, if clinically stable for > 3 months -5q-minus syndrome allowed, if lenalidomide unsuccessful or unavailable at the time of inclusion -IPSS score < intermediate-1 -transfusion dependent or Hb < 10,5 g/dl -History of less than 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs), except for tranfusions for acute bleeding -Serum ferritin > 300 µg/l and < 1500 μg/l. This level should have been verified at least at two occasions within 3 months. Samples must be obtained in the absence of concomitant severe infection -no indication for EPO (due to high endogenous EPO levels) or EPO without benefit in the past -no indication and/or no plans for cytostatic drugs -no previous exposure to cytostatic drugs, thalidomide, lenalidomide, G-CSF or EPO or exposure to any of these drugs has been terminated since > 8 weeks (4 weeks for G-CSF). -no indication and/or no plans for stem cell transplantation -stable or worsening cytopenia during the past 8 weeks. If in doubt, extend screening period to > 8 weeks -Patients of either gender and age > 18 years -Life expectancy > 12 months -Females of childbearing potential must use double-barrier contraception. -Written informed consent by the patient
|
|
E.4 | Principal exclusion criteria |
-Treatment with deferasirox or other chelation therapy for periods > 4 weeks before study start -Patients with a concomitant second malignant disease, possibly interfering with life expectancy -Patients with mean levels of alanine aminotransferase (ALT) > 5x ULN -Patients with uncontrolled systemic hypertension -Patients with serum creatinine > 1.5x the upper limit of normal (ULN) or a creatinine clearance < 60 ml/min according to the MDRD formula (Levey 2005) -History of nephrotic syndrome -Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment -Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing study treatment -Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days -Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following: *history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding; *history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; *history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase; *history of urinary obstruction or difficulty in voiding -History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative -History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the run-in period -Patients with active uncontrolled infectious disease -Pregnancy or breast feeding -QT > 470 msec on screening ECG -Patients with a history of Torsades de Pointes |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Fraction of patients with hematologic improvement according to modified IWG criteria (reduction of transfusions and/or increase in Hb, improvement of neutropenia and thrombocytopenia) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |